Clinical Trials Browser

Phase 1/2 × INDUSTRY × ensartinib × Clear all

NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Phase 1/2 Recruiting

Solid Advanced Tumor

NCT01625234 2021-10-06

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms